{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:12Z","timestamp":1707524472274},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,21]]},"DOI":"10.7759\/cureus.22422","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T09:27:35Z","timestamp":1645435655000},"source":"Crossref","is-referenced-by-count":0,"title":["Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Lauren  J","family":"Pelkey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David  M","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H","family":"Zakem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle  M","family":"Muza-Moons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison DE","year":"2008","unstructured":"Rollison DE, Howlader N, Smith MT, et al.. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008, 112:45-52. 10.1182\/blood-2008-01-134858","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik MM","year":"2018","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol. 2018, 93:824-40. 10.1002\/ajh.25104","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such E","year":"2011","unstructured":"Such E, Cervera J, Costa D, et al.. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011, 96:375-83. 10.3324\/haematol.2010.030957","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik MM","year":"2016","unstructured":"Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood Cancer J. 2016, 6:10.1038\/bcj.2016.5","journal-title":"Blood Cancer J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson R","year":"2018","unstructured":"Itzykson R, Fenaux P, Bowen D, et al.. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet. Hemasphere. 2018, 2:10.1097\/HS9.0000000000000150","journal-title":"Hemasphere"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing U","year":"2004","unstructured":"Germing U, K\u00fcndgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma. 2004, 45:1311-8. 10.1080\/1042819042000207271","journal-title":"Leuk Lymphoma"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01152-1","article-title":"Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease","volume":"35","author":"Zhao LP","year":"2021","unstructured":"Zhao LP, Boy M, Azoulay C, et al.. Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021, 35:2720-4. 10.1038\/s41375-021-01152-1","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev294","article-title":"Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study","volume":"55","author":"Mekinian A","year":"2016","unstructured":"Mekinian A, Grignano E, Braun T, et al.. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016, 55:291-300. 10.1093\/rheumatology\/kev294","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222059","article-title":"Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions","volume":"104","author":"Valent P","year":"2019","unstructured":"Valent P, Orazi A, Savona MR, et al.. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019, 104:1935-49. 10.3324\/haematol.2019.222059","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson SY","year":"2010","unstructured":"Kristinsson SY, Landgren O, Samuelsson J, Bj\u00f6rkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010, 95:1216-20. 10.3324\/haematol.2009.020412","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.10.026","article-title":"Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis","volume":"85","author":"Hu Z","year":"2019","unstructured":"Hu Z, Ramos CE, Medeiros LJ, et al.. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis. Hum Pathol. 2019, 85:290-8. 10.1016\/j.humpath.2018.10.026","journal-title":"Hum Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3289-6","article-title":"Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia","volume":"97","author":"Khan M","year":"2018","unstructured":"Khan M, Muzzafar T, Kantarjian H, et al.. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. 2018, 97:1183-91. 10.1007\/s00277-018-3289-6","journal-title":"Ann Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang Q","year":"2015","unstructured":"Zhang Q, Zhao K, Shen Q, et al.. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015, 525:389-93. 10.1038\/nature15252","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8540","article-title":"Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes","volume":"29","author":"Kristinsson SY","year":"2011","unstructured":"Kristinsson SY, Bj\u00f6rkholm M, Hultcrantz M, Derolf \u00c5R, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011, 29:2897-903. 10.1200\/JCO.2011.34.8540","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron E","year":"2013","unstructured":"Padron E, Painter JS, Kunigal S, et al.. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013, 121:5068-77. 10.1182\/blood-2012-10-460170","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson R","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, et al.. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013, 121:2186-98. 10.1182\/blood-2012-06-440347","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout C","year":"2006","unstructured":"Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006, 108:1652-60. 10.1182\/blood-2006-02-002030","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16790","article-title":"Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study","volume":"192","author":"Berggren DM","year":"2021","unstructured":"Berggren DM, Kjellander M, Backlund E, et al.. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. Br J Haematol. 2021, 192:474-83. 10.1111\/bjh.16790","journal-title":"Br J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2015.1070835","article-title":"Decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients","volume":"48","author":"Mohammadnia-Afrouzi M","year":"2015","unstructured":"Mohammadnia-Afrouzi M, Hosseini AZ, Khalili A, Abediankenari S, Hosseini V, Maleki I. Decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients. Autoimmunity. 2015, 48:556-61. 10.3109\/08916934.2015.1070835","journal-title":"Autoimmunity"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1375.031","article-title":"Upregulation of Foxp3 expression in mouse and human Treg is IL-2\/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis","volume":"1079","author":"Murawski MR","year":"2006","unstructured":"Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2\/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci. 2006, 1079:198-204. 10.1196\/annals.1375.031","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/348530","article-title":"Potential role of NK cells in the pathogenesis of inflammatory bowel disease","volume":"2011","author":"Yadav PK","year":"2011","unstructured":"Yadav PK, Chen C, Liu Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J Biomed Biotechnol. 2011, 2011:10.1155\/2011\/348530","journal-title":"J Biomed Biotechnol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells","volume":"10","author":"Carlsten M","year":"2019","unstructured":"Carlsten M, J\u00e4r\u00e5s M. Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front Immunol. 2019, 10:10.3389\/fimmu.2019.02357","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2012.140","article-title":"Natural killer cells protect mice from DSS-induced colitis by regulating neutrophil function via the NKG2A receptor","volume":"6","author":"Hall LJ","year":"2013","unstructured":"Hall LJ, Murphy CT, Quinlan A, Hurley G, Shanahan F, Nally K, Melgar S. Natural killer cells protect mice from DSS-induced colitis by regulating neutrophil function via the NKG2A receptor. Mucosal Immunol. 2013, 6:1016-26. 10.1038\/mi.2012.140","journal-title":"Mucosal Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/421702","article-title":"Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications","volume":"2012","author":"Farnault L","year":"2012","unstructured":"Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol. 2012, 2012:10.1155\/2012\/421702","journal-title":"Clin Dev Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa696","article-title":"Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report","volume":"60","author":"Corfmat M","year":"2021","unstructured":"Corfmat M, Willekens C, Vinit J, et al.. Low dose IL-2 in patients with steroid-dependent dysimmune manifestations associated with myelodysplastic syndromes: a three-case report. Rheumatology (Oxford). 2021, 60:3404-8. 10.1093\/rheumatology\/keaa696","journal-title":"Rheumatology (Oxford)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.01.053","article-title":"Low dose IL-2 for the treatment of moderate to severe ulcerative colitis","volume":"160","author":"Allegretti J","year":"2021","unstructured":"Allegretti J, Canavan J, Mitsialis V, et al.. Low dose IL-2 for the treatment of moderate to severe ulcerative colitis. Gastroenterology. 2021, 160:9-10. 10.1053\/j.gastro.2021.01.053","journal-title":"Gastroenterology"},{"key":"ref28","unstructured":"A study of HDC\/IL-2 treatment in chronic myelomonocytic leukemia (CMML). (2017). Accessed. August 24, 2021: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03040401."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.23812\/20-1-E","article-title":"Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy","volume":"34","author":"Conti P","year":"2020","unstructured":"Conti P, Caraffa A, Gallenga CE, et al.. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. J Biol Regul Homeost Agents. 2020, 34:1971-5. 10.23812\/20-1-E","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051513","article-title":"Location first: targeting acute myeloid leukemia within its niche","volume":"9","author":"Pievani A","year":"2020","unstructured":"Pievani A, Biondi M, Tomasoni C, Biondi A, Serafini M. Location first: targeting acute myeloid leukemia within its niche. J Clin Med. 2020, 9:10.3390\/jcm9051513","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/86627-coexistence-of-chronic-myelomonocytic-leukemia-and-ulcerative-colitis-with-rapid-progression-to-acute-myelomonocytic-leukemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:04Z","timestamp":1707507964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/86627-coexistence-of-chronic-myelomonocytic-leukemia-and-ulcerative-colitis-with-rapid-progression-to-acute-myelomonocytic-leukemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.22422","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,21]]}}}